A Study of Emapalumab for Pediatric Aplastic Anemia (NCT06430788)
Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic Anemia
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Funding Source- FDA OOPD
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
Age range: 0 Years to 25 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Cincinnati Children's Hospital Medical Center (Data collection only) — Cincinnati, Ohio
- Children's Hospital of Philadelphia (Data Collection AND Specimen Analysis) — Philadelphia, Pennsylvania
- Virginia Commonwealth University (Data Collection Only ) — Richmond, Virginia
- Children's Hospital of Wisconsin (Data Collection Only) — Milwaukee, Wisconsin
- Medical College of Wisconsin (Data Collection AND Data Analysis) — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (800) 525-2225
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Aplastic Anemia
- Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia — Seattle, Washington
- UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia — Iowa City, Iowa
- Haploidentical HCT for Severe Aplastic Anemia — Memphis, Tennessee
- Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome — Houston, Texas
Explore by condition: All Aplastic Anemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.